MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts - WLTZ 38 | Columbus Georgia Regional News & Community

MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, May 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts

http://www.reportlinker.com/p02114424/MediPoint-Neurovascular-Interventions---EU-Analysis-and-Market-Forecasts.html

MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts

Summary

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

The neurovascular interventions market in the 5EU is a vast and dynamic market that consists of innovative and emerging technologies. Neurointerventional devices can be used to treat a variety of cerebrovascular indications such as intracranial aneurysms, AVMs, and dural AVFs, atherosclerotic disease, and stroke. In this report, the neurointerventional market encompasses embolization, revascularization, mechanical thrombectomy, and access/support devices.

Scope

- An overview of Neurovascular, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the EU Neurovascular market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
- Investigation of current and future market competition for Neurovascular.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.

- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Neurovascular sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

- Understand the trends shaping and driving the EU Neurovascular market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the EU Neurovascular market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in the EU Neurovascular market landscape? Identify, understand and capitalize.

1 Table of Contents

2 Introduction 27
2.1 Catalyst 28
3 Clinical Outcomes 29
3.1 Disease Management 29
3.1.1 Intracranial Aneurysms 29
3.1.2 Intracranial Arteriovenous Malformations 30
3.1.3 Dural Arteriovenous Fistulas 31
3.1.4 Intracranial and Extracranial Atherosclerotic Disease 31
3.1.5 Stroke 32
3.2 Treatment Modalities 33
3.2.1 Overview 33
3.2.2 Medical/Chemical Therapy 34
3.2.3 Surgical Therapy 35
3.2.4 Endovascular Therapy 37
4 Industry Overview 47

4.1 Overview 47
4.2 Procedure Trends 47
4.2.1 Intracranial Aneurysms 47
4.2.2 Intracranial Arteriovenous Malformations 49
4.2.3 Atherosclerotic Disease 50
4.2.4 Acute Ischemic Stroke 51
4.3 Market Access 52
4.3.1 Regulatory Process 54
4.3.2 Physician Perception and Decision Making Process 55
4.3.3 Variations in Clinical Practice 61
4.3.4 Lack of Clinical Data 61
4.3.5 Regional-Level Control 62
4.3.6 Cost-Considerations 63
4.3.7 Reimbursement Trends 64
4.4 Regulatory Issues/Recalls 67
4.4.1 Regulatory Issues 67
4.5 Mergers and Acquisitions/Key Partnerships 67
4.5.1 Covidien and Nfocus Neuromedical 67
4.5.2 Stryker Corporation and Surpass Medical 68
4.5.3 Covidien and MindFrame 68
4.5.4 Covidien and Reverse Medical Corporation 69
4.5.5 Stryker Corporation and Boston Scientific Neurovascular 69
4.5.6 Stryker Corporation and Concentric Medical 69
4.5.7 Covidien and ev3 70

4.5.8 Medtronic and Invatec 70
4.5.9 Johnson & Johnson and Micrus Endovascular 71
4.5.10 ev3 and Chestnut Medical Technologies 71
4.5.11 Boston Scientific Corporation and Guidant Corporation 72
4.6 Economic Impact 72
4.6.1 Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations 72
4.6.2 Economic Impact of Stroke 73
5 Unmet Needs 75
5.1 Overview 75
5.2 Need for Practice, Performance, and Physician Training Guidelines 75
5.3 Lack of Clinical Data 76
5.4 Improve Management of Acute Ischemic Stroke 77
5.5 Address Complications of Surgical Therapy 78
5.6 Addressing the Challenges of Surgical Clipping 79
5.7 Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms 80
5.8 Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes 81
5.9 Difficulty in Treating Intracranial Arteriovenous Malformations 82
5.10 Eliminating Mechanisms of Failure with Balloon Angioplasty 83
5.11 Addressing Challenges of Neurovascular Stenting 84
5.11.1 Risk of Post-Procedural Complications 84
5.11.2 In-Stent Restenosis 85
5.11.3 Stent Navigation 85
5.12 Complications of Dual Antiplatelet Therapy 86
5.13 Need to Improve Medical Therapy 86

5.14 Improve Ease of Access 87
6 Market Opportunity Analysis 88
6.1 Neurovascular Interventions Market 88
6.2 Improve Neurointerventional Device Design 88
6.3 Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations 90
6.3.1 Intracranial Aneurysms 90
6.3.2 Intracranial Arteriovenous Malformations 91
6.4 Target Challenging Patient Populations 91
6.5 Optimize Care for Acute Ischemic Stroke Patients 92
6.6 Development of Drug-Eluting Devices 93
6.7 Emerging Markets 94
7 Market Drivers and Barriers 95
7.1 Market Drivers 95
7.1.1 Rising Prevalence of Disease 96
7.1.2 Improved Clinical Outcomes with Endovascular Coiling 97
7.1.3 Remodeling Techniques with Stent and Balloon-Assisted Coiling 98
7.1.4 Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms 100
7.1.5 Alternative Non-Coiling Embolization Devices for Aneurysm Treatment 101
7.1.6 Endovascular Embolization of Intracranial Arteriovenous Malformations 102
7.1.7 Imaging Assessment for Intracranial Arteriovenous Malformation Treatment 103
7.1.8 Stenting for Carotid Atherosclerotic Disease 103
7.1.9 Low-Profile Stent Systems 104
7.1.10 Improved Recanalization Rates with Mechanical Thrombectomy Devices 105
7.1.11 Cost Savings 107
7.1.12 Availability of Long-Term and Cost-Effective Data 107

7.2 Market Barriers 108
7.2.1 Complications of Neurointerventional Procedures and Devices 108
7.2.2 Lack of Clinical Data 114
7.2.3 High Cost of Treatment 114
7.2.4 Lack of Reimbursement 116
7.2.5 Lack of Superiority of Bioactive/Coated Coils 117
7.2.6 Alternative Technologies for Stroke Therapy 118
7.2.7 Regulatory Challenges: US Food and Drug Administration and European Conformity Mark 118
7.2.8 Healthcare Cost-Cutting and Reimbursement 119
7.2.9 Availability of Venture Capital 120
7.2.10 Medical Device Excise Tax 121
8 Competitive Assessment 122
8.1 Overview 122
8.2 5EU Market Share 122
8.3 Marketed Products 123
8.3.1 Aachen Resonance 123
8.3.2 Abbott Vascular 125
8.3.3 Acandis 127
8.3.4 B. Braun 129
8.3.5 BALT Extrusion 130
8.3.6 Blockade Medical 136
8.3.7 Boston Scientific Corporation 137
8.3.8 Contego Medical 139
8.3.9 Cook Medical 139
8.3.10 Covidien 140
8.3.11 Gardia Medical 147
8.3.12 Gore Medical 148

8.3.13 InspireMD 150
8.3.14 ITGI Medical 151
8.3.15 Johnson & Johnson 152
8.3.16 Medikit 159
8.3.17 Medtronic 161
8.3.18 Merlin MD 163
8.3.19 MicroPort Scientific Corporation 165
8.3.20 Minvasys 167
8.3.21 Neuravi 168
8.3.22 Optimed 169
8.3.23 Penumbra 170
8.3.24 Phenox GmbH 174
8.3.25 Reverse Medical 176
8.3.26 Sequent Medical 178
8.3.27 Stryker Neurovascular Intervention 180
8.3.28 Terumo Corporation 186
8.3.29 Valor Medical 194
9 Pipeline Assessment 196
9.1 Overview 196
9.2 Pipeline by Stage of Development 196
9.3 Product Profiles 198
9.3.1 Aneurysm Occlusion Saddle 198
9.3.2 Ballstent Microcatheter 199
9.3.3 Blood Clot Removing Device 199
9.3.4 EKOS' EkoSonic Small Vessel Endovascular System 200
9.3.5 Flow-Diverting Thin-Film Nitinol Covered Stent 200
9.3.6 Ischemic Stroke System 201

9.3.7 Janjua Aneurysm Net 202
9.3.8 Multilayer Aneurysm Repair System 202
9.3.9 NAVIMAX 203
9.3.10 Palmaz Scientific Stents 204
9.3.11 Silk Road System 205
9.3.12 Transcranial Thrombectomy Catheter 206
10 Clinical Trial Analysis 207
10.1 Overview 207
10.2 Clinical Trials to Watch 208
10.2.1 Embolization 208
10.2.2 Flow Diversion 210
10.2.3 Revascularization 213
10.2.4 Mechanical Thrombectomy 214
11 Current and Future Players 217
11.1 Overview 217
11.2 Trends in Corporate Strategy 217
11.3 Company Profiles 219
11.3.1 BALT Extrusion 219
11.3.2 Covidien 222
11.3.3 Johnson & Johnson 225
11.3.4 Penumbra 230
11.3.5 Stryker Corporation 233
11.3.6 Terumo Corporation 235
11.3.7 Abbott Vascular 239
11.3.8 Boston Scientific Corporation 241
11.3.9 Cook Medical 243
11.3.10 Gore Medical 245
11.3.11 Medtronic 247
11.3.12 Aachen Resonance 250
11.3.13 Acandis 252
11.3.14 B. Braun 254
11.3.15 Blockade Medical 255
11.3.16 Contego Medical 257
11.3.17 Gardia Medical 258

11.3.18 InspireMD 260
11.3.19 ITGI Medical 262
11.3.20 Medikit 263
11.3.21 Merlin MD 264
11.3.22 MicroPort Scientific Corporation 266
11.3.23 Minvasys 267
11.3.24 Neuravi 269
11.3.25 Optimed 270
11.3.26 Phenox GmBH 272
11.3.27 Reverse Medical 273
11.3.28 Sequent Medical 275
11.3.29 Valor Medical 276
11.3.30 Other Companies 279
12 Market Outlooks 281
12.1 Overview 281
12.2 Country-Specific Market Outlook 282
12.2.1 France 283

12.2.2 Germany 289
12.2.3 Italy 295
12.2.4 Spain 300
12.2.5 United Kingdom 306
13 Appendix 313
13.1 Bibliography 313
13.2 Abbreviations 335
13.3 Report Methodology 340
13.3.1 Overview 340
13.3.2 Coverage 340
13.3.3 Secondary Research 340
13.4 Physicians and Specialists Included in this Study 342
13.4.1 Vivek Gupta, MD 342
13.4.2 Zsolt Kulscár, MD, PhD 342
13.4.3 Salvatore Mangiafico, MD 342
13.4.4 Thanh Nguyen, MD, FRCPc 342
13.4.5 Eduardo Wajnberg, MD 342
13.4.6 Phil White, MD 342

13.4.7 Osama O Zaidat, MD, MS, FAAN, FAHA 343
13.5 Primary Research 344
13.5.1 Primary Research - Key Opinion Leader Interviews 344
13.5.2 Expert Panel Validation 344
13.6 Forecasting Methodology 345
13.7 About the Authors 347
13.7.1 Analysts 347
13.7.2 Global Head of Healthcare 348
13.8 About MediPoint 349
13.9 About GlobalData 349
13.10 Disclaimer 349

1.1 List of Tables

Table 1: Complications of Cerebral Artery Bypass Surgery 36
Table 2: Types of Cerebral Embolic Protection Devices 44
Table 3: Aachen Resonance Neurovascular Intervention Marketed Product 123
Table 4: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 125
Table 5: Abbott Vascular Neurovascular Intervention Marketed Products 126
Table 6: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 127
Table 7: Acandis Neurovascular Intervention Marketed Products 128
Table 8: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 129
Table 9: B. Braun Neurovascular Intervention Marketed Product 130
Table 10: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 130
Table 11: BALT Extrusion Neurovascular Intervention Marketed Products 132
Table 12: BALT Extrusion Neurovascular Intervention Marketed Access Products 134
Table 13: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 135
Table 14: Blockade Medical Neurovascular Intervention Marketed Product 136
Table 15: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 137

Table 16: Boston Scientific Neurovascular Intervention Marketed Products 138
Table 17: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 138
Table 18: Contego Medical Neurovascular Intervention Marketed Product 139
Table 19: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 139
Table 20: Cook Medical Neurovascular Intervention Marketed Products 140
Table 21: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 140
Table 22: Covidien Neurovascular Interventional Marketed Products 142
Table 23: Covidien Neurovascular Intervention Marketed Access Products 145
Table 24: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 146
Table 25: Gardia Medical Neurovascular Intervention Marketed Product 147
Table 26: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 148
Table 27: Gore Medical Neurovascular Intervention Marketed Products 149
Table 28: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 149
Table 29: InspireMD Neurovascular Intervention Marketed Product 150
Table 30: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 150
Table 31: ITGI Medical Neurovascular Intervention Marketed Product 151
Table 32: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 152
Table 33: Codman Neurovascular Marketed Embolization Products 154
Table 34: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products 156
Table 35: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 157
Table 36: Cordis Corporation Marketed Neurointerventional Products 158
Table 37: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 159

Table 38: Medikit Neurovascular Intervention Marketed Products 160
Table 39: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 161
Table 40: Medtronic Neurovascular Intervention Marketed Products 162
Table 41: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 163
Table 42: Merlin MD Neurovascular Intervention Marketed Product 164
Table 43: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 165
Table 44: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products 166
Table 45: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 167
Table 46: Minvasys Neurovascular Intervention Marketed Product 168
Table 47: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 168
Table 48: Neuravi Neurovascular Intervention Marketed Product 169
Table 49: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 169
Table 50: Optimed Neurovascular Intervention Marketed Products 170
Table 51: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 170
Table 52: Penumbra Neurovascular Intervention Marketed Products 171
Table 53: Penumbra Marketed Neurovascular Access Products 173
Table 54: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 174
Table 55: Phenox GmbH Neurovascular Intervention Marketed Products 175
Table 56: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 176
Table 57: Reverse Medical Neurovascular Intervention Marketed Products 177
Table 58: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 178
Table 59: Sequent Medical Neurovascular Intervention Marketed Products 179
Table 60: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 180
Table 61: Stryker Neurovascular Intervention Marketed Products 182
Table 62: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products 184
Table 63: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 186
Table 64: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products 188

Table 65: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014 189
Table 66: MicroVention Neurovascular Intervention Marketed Products 191
Table 67: MicroVention Marketed Neurovascular Access Products 193
Table 68: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014 194
Table 69: Valor Medical Neurovascular Intervention Marketed Products 195
Table 70: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014 195
Table 71: Global Neurovascular Interventions Pipeline Products 198
Table 72: Aneurysm Occlusion Saddle SWOT Analysis, 2014 199
Table 73: EKOS EkoSonic SV System SWOT Analysis, 2014 200
Table 74: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014 201
Table 75: Janjua Aneurysm Net SWOT Analysis, 2014 202
Table 76: Multilayer Aneurysm Repair System SWOT Analysis, 2014 203
Table 77: NAVIMAX SWOT Analysis, 2014 204
Table 78: Palmaz Scientific Stents SWOT Analysis, 2014 205
Table 79: Silk Road System SWOT Analysis, 2014 206
Table 80: BALT Extrusion Company Profile 220
Table 81: BALT Extrusion Neurovascular Intervention Marketed Products 221
Table 82: BALT Extrusion SWOT Analysis, 2014 222
Table 83: Covidien Company Profile 223
Table 84: Covidien Neurovascular Intervention Marketed Products 224
Table 85: Covidien SWOT Analysis, 2014 225
Table 86: Codman & Shurtleff Company Profile 226
Table 87: Codman & Shurtleff Neurovascular Intervention Marketed Products 227
Table 88: Codman & Shurtleff SWOT Analysis, 2014 228
Table 89: Cordis Corporation Company Profile 228
Table 90: Cordis Corporation Neurovascular Intervention Marketed Products 229
Table 91: Cordis Corporation SWOT Analysis, 2014 230
Table 92: Penumbra Company Profile 230

Table 93: Penumbra Neurovascular Intervention Marketed Products 232
Table 94: Penumbra SWOT Analysis, 2014 232
Table 95: Stryker Corporation Company Profile 233
Table 96: Stryker Corporation Neurovascular Intervention Marketed Products 234
Table 97: Stryker Corporation SWOT Analysis, 2014 235
Table 98: Terumo Corporation Company Profile 236
Table 99: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products 237
Table 100: MicroVention Neurovascular Intervention Marketed Products 238
Table 101: Terumo Corporation SWOT Analysis, 2014 239
Table 102: Abbott Vascular Company Profile 239
Table 103: Abbott Vascular Neurovascular Intervention Marketed Products 240
Table 104: Abbott Vascular SWOT Analysis, 2014 241
Table 105: Boston Scientific Corporation Company Profile 242
Table 106: Boston Scientific Neurovascular Intervention Marketed Products 242
Table 107: Boston Scientific Corporation SWOT Analysis, 2014 243
Table 108: Cook Medical Company Profile 243
Table 109: Cook Medical Neurovascular Intervention Marketed Products 244
Table 110: Cook Medical SWOT Analysis, 2014 245
Table 111: Gore Medical Company Profile 246
Table 112: Gore Medical Neurovascular Intervention Marketed Products 246
Table 113: Gore Medical SWOT Analysis, 2014 247
Table 114: Medtronic Company Profile 248
Table 115: Medtronic Neurovascular Intervention Marketed Products 249
Table 116: Medtronic SWOT Analysis, 2014 249

Table 117: Aachen Resonance Company Profile 250
Table 118: Aachen Resonance Neurovascular Intervention Marketed Product 251
Table 119: Aachen Resonance SWOT Analysis, 2014 251
Table 120: Acandis Company Profile 252
Table 121: Acandis Neurovascular Intervention Marketed Products 253
Table 122: Acandis SWOT Analysis, 2014 253
Table 123: B. Braun Company Profile 254
Table 124: B. Braun Neurovascular Intervention Marketed Product 255
Table 125: B. Braun SWOT Analysis, 2014 255
Table 126: Blockade Medical Company Profile 256
Table 127: Blockade Medical Neurovascular Intervention Marketed Product 256
Table 128: Blockade Medical SWOT Analysis, 2014 257
Table 129: Contego Medical Company Profile 257
Table 130: Contego Medical Neurovascular Intervention Marketed Product 258
Table 131: Contego Medical SWOT Analysis, 2014 258
Table 132: Gardia Medical Company Profile 259
Table 133: Gardia Medical Neurovascular Intervention Marketed Product 259
Table 134: Gardia Medical SWOT Analysis, 2014 260
Table 135: InspireMD Company Profile 261
Table 136: InspireMD Neurovascular Intervention Marketed Product 261
Table 137: InspireMD SWOT Analysis, 2014 261
Table 138: ITGI Medical Company Profile 262
Table 139: ITGI Medical Neurovascular Intervention Marketed Product 262
Table 140: ITGI Medical SWOT Analysis, 2014 263
Table 141: Medikit Company Profile 263
Table 142: Medikit Neurovascular Intervention Marketed Products 264
Table 143: Medikit SWOT Analysis, 2014 264

Table 144: Merlin MD Company Profile 265
Table 145: Merlin MD Neurovascular Intervention Marketed Product 265
Table 146: Merlin MD SWOT Analysis, 2014 265
Table 147: MicroPort Scientific Corporation Company Profile 266
Table 148: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products 266
Table 149: MicroPort Scientific Corporation SWOT Analysis, 2014 267
Table 150: Minvasys Company Profile 268
Table 151: Minvasys Neurovascular Intervention Marketed Product 268
Table 152: Minvasys SWOT Analysis, 2014 268
Table 153: Neuravi Company Profile 269
Table 154: Neuravi Neurovascular Intervention Marketed Product 269
Table 155: Neuravi SWOT Analysis, 2014 270
Table 156: Optimed Company Profile 271
Table 157: Optimed Neurovascular Intervention Marketed Products 271
Table 158: Optimed SWOT Analysis, 2014 271
Table 159: Phenox GmBH Company Profile 272
Table 160: Phenox GmbH Neurovascular Intervention Marketed Products 273
Table 161: Phenox GmBH SWOT Analysis, 2014 273
Table 162: Reverse Medical Company Profile 274
Table 163: Reverse Medical Neurovascular Intervention Marketed Products 274
Table 164: Reverse Medical SWOT Analysis, 2014 275
Table 165: Sequent Medical Company Profile 275
Table 166: Sequent Medical Neurovascular Intervention Marketed Products 276
Table 167: Sequent Medical SWOT Analysis, 2014 276
Table 168: Valor Medical Company Profile 277
Table 169: Valor Medical Neurovascular Intervention Marketed Products 277
Table 170: Valor Medical SWOT Analysis, 2014 278
Table 171: Other Companies in the Neurovascular Intervention Market, 2014 279
Table 172: Neurovascular Interventions Market Sales ($m) Forecast for France, 2011–2020 284
Table 173: Neurovascular Interventions Market Sales ($m) Forecast for Germany, 2011–2020 290
Table 174: Neurovascular Interventions Market Sales ($m) Forecast for Italy, 2011–2020 296
Table 175: Neurovascular Interventions Market Sales ($m) Forecast for Spain, 2011–2020 301
Table 176: Neurovascular Interventions Market Sales ($m) Forecast for the UK, 2011–2020 307

1.2 List of Figures

Figure 1: Treatment Modalities - Neurovascular Interventions 34
Figure 2: Types of Stents Used for Neurovascular Interventions 43
Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, 5EU, 2011-2020 49
Figure 4: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, 5EU, 2011-2020 50
Figure 5: Revascularization Procedure Volume for Treating Atherosclerotic Disease, 5EU, 2011-2020 51
Figure 6: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, 5EU, 2011-2020 52
Figure 7: Neurointerventional Market Distribution, 5EU, 2013 122
Figure 8: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014 197
Figure 9: Neurovascular Interventions Market ($m) for Treating Cerebrovascular Disease, 5EU, 2011-2020 281
Figure 10: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, 5EU, 2013 282
Figure 11: Neurovascular Interventions Market Revenue ($m), 5EU, 2013 and 2020 283
Figure 12: French Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 285
Figure 13: French Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 286
Figure 14: French Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 287
Figure 15: French Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 288
Figure 16: French Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 289
Figure 17: German Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 290

Figure 18: German Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 292
Figure 19: German Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 293
Figure 20: German Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 294
Figure 21: German Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 295
Figure 22: Italian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 296
Figure 23: Italian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 297
Figure 24: Italian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 298
Figure 25: Italian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 299
Figure 26: Italian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 300
Figure 27: Spanish Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 302
Figure 28: Spanish Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 303
Figure 29: Spanish Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 304
Figure 30: Spanish Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 305
Figure 31: Spanish Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 306
Figure 32: UK Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020 307
Figure 33: UK Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020 309
Figure 34: UK Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020 310
Figure 35: UK Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020 311
Figure 36: UK Access Device Market ($m) for Cerebrovascular Applications, 2011-2020 312

To order this report: MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts
http://www.reportlinker.com/p02114424/MediPoint-Neurovascular-Interventions---EU-Analysis-and-Market-Forecasts.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WLTZ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.